Related Experiment Video
Updated: Jun 13, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Interim analyses of a first-in-human phase 1/2 mRNA trial for propionic acidaemia
Dwight Koeberl1, Andreas Schulze2, Neal Sondheimer2
1Duke University School of Medicine, Durham, NC, USA.
This study evaluated mRNA-3927, a novel therapy for propionic acidemia. Preliminary results show a 70% reduction in metabolic decompensation events, indicating potential therapeutic benefit.
Area of Science:
- Biochemistry
- Genetics
- Pharmacology
Background:
- Propionic acidemia is a rare genetic metabolic disorder.
- Caused by defects in propionyl-coenzyme A carboxylase (PCCA or PCCB) subunits.
- Leads to toxic metabolite accumulation and life-threatening decompensation events.
Purpose of the Study:
- To evaluate the safety and efficacy of mRNA-3927, a dual mRNA therapy.
- mRNA-3927 encodes for PCCA and PCCB subunits.
- Interim analysis of a phase 1/2, open-label, dose-optimization study.
Main Methods:
- First-in-human study of mRNA-3927.
- 16 participants enrolled across 5 dose cohorts.
- Intravenous administration of mRNA-3927 over 15.69 person-years.
Main Results:
- No dose-limiting toxicities observed.
- Treatment-emergent adverse events in 93.8% of participants.
- Preliminary analysis shows dose-dependent exposure and a 70% reduction in metabolic decompensation events.
Conclusions:
- mRNA-3927 demonstrates a favorable safety profile in early-stage trials.
- Preliminary efficacy suggests a significant reduction in metabolic decompensation events.
- Further investigation is warranted to confirm therapeutic potential for propionic acidemia.
Related Concept Videos
Phase II Reactions: Acetylation Reactions
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
Bioavailability Study Design: Healthy Subjects Versus Patients
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

